| Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder. | |
| | |
MedLine Citation:
|
PMID: 19865002 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
The effect of valproate on the steady-state plasma concentrations of olanzapine was investigated in 18 patients with bipolar or schizoaffective disorder. Additional valproate, at a dose ranging from 600 to 2000 mg/d, was administered for 4 weeks to patients stabilized on olanzapine (5-20 mg/d). During valproate coadministration, mean plasma olanzapine concentrations decreased significantly from 32.9 +/- 9.7 ng/mL at baseline to 27.4 +/- 9.8 ng/mL at week 2 (P = 0.02), and to 26.9 +/- 9.2 ng/mL at week 4 (P = 0.001). Smoking also decreased plasma olanzapine concentrations. Valproate coadministration with olanzapine was well tolerated and no patient showed a worsening of his or her psychopathological condition. These findings indicate that valproate, at doses of up to 2000 mg/d, is associated with a minimal, presumably not clinically significant, decrease in plasma olanzapine concentrations, possibly as a result of induction of olanzapine metabolism. New studies are needed to confirm that valproate could have mild inductive effects. |
| | |
Authors:
|
Edoardo Spina; Concetta D'Arrigo; Vincenza Santoro; Maria Rosaria Muscatello; Gianluca Pandolfo; Rocco Zoccali; Francisco J Diaz; Jose de Leon |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Therapeutic drug monitoring Volume: 31 ISSN: 1536-3694 ISO Abbreviation: Ther Drug Monit Publication Date: 2009 Dec |
Date Detail:
|
Created Date: 2009-11-25 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7909660 Medline TA: Ther Drug Monit Country: United States |
Other Details:
|
Languages: eng Pagination: 758-63 Citation Subset: IM |
Affiliation:
|
Section of Pharmacology, Department of Clinical and Experimental Medicine and Pharmacology, University of Messina and IRCCS Centro Neurolesi Bonino-Pulejo, Messina, Italy. espina@unime.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Simultaneous Quantification of Erlotinib, Gefitinib, and Imatinib in Human Plasma by Liquid Chromato...
Next Document: Defining a Lowest Observable Adverse Effect Hair Concentrations of Mercury for Neurodevelopmental Ef...